ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $8.122 million which beat the analyst consensus estimate of $7.780 million by 4.40 percent. This is a 40.96 percent increase over sales of $5.762 million the same period last year.